NBIX
NASDAQ · Biotechnology
Neurocrine Biosciences Inc
$166.06
+4.62 (+2.86%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+15.61%
1Y
+29.96%
YTD
+18.11%
Open$163.43
Previous Close$161.44
Day High$168.58
Day Low$162.34
52W High$169.57
52W Low$122.14
Volume—
Avg Volume1.18M
Market Cap15.92B
P/E Ratio23.81
EPS$6.50
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$139.44
Above
SMA 200
$135.94
Above
RSI (14)
38.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
36 analysts
Price Target
-23.6% upside
Current
$166.06
$166.06
Target
$126.93
$126.93
$104.30
$126.93 avg
$177.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.81B | 2.26B | 5.53B |
| Net Income | 469.50M | 339.89M | 497.45M |
| Profit Margin | 16.7% | 15.9% | 9.0% |
| EBITDA | 632.83M | 483.58M | 909.27M |
| Free Cash Flow | — | — | 422.12M |
| Rev Growth | +24.3% | +24.3% | -8.7% |
| Debt/Equity | — | — | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |